I am very pleased to provide you with the terms of your anticipated employment with Response Genetics, Inc. (“Response Genetics” or the “Company”). The details of the Company’s offer (the “Offer”) are set forth below. Please contact me if you have any questions about the terms in this Offer. We look forward to working with you.

1. Position. Your position will be Vice President and General Counsel (“GC”), reporting to the Company’s Chief Executive Officer (“CEO”). You will work at our Maryland location. As a Response Genetics employee, we expect that you will perform any and all duties and responsibilities associated with your position in a satisfactory manner and to the best of your abilities at all times.

Your principle responsibilities will include the following: (1) overall management of legal operations of the Company; (2) provide legal counsel regarding transactional matters, primarily including drafting, reviewing and negotiating agreements related to: licensing of intellectual property and related collaborations, the transfer of biological materials, various service agreements performed for the Company by third party vendors such as outside laboratories and other consultants; (3) identifying and securing intellectual property protection for inventions and discoveries made by or licensed to the Company, including developing strategy for the Company on how to develop an area and to strengthen patents to support the Company’s business; (4) work with outside counsel to file and prosecute U.S. and foreign patent applications; (5) provide counsel to internal management with respect to fulfilling contractual obligations under licensing and collaboration agreements; (6) participation in road show; and (7) performing responsibilities that are normally associated with the General Counsel position and as otherwise may be assigned to you from time to time by the CEO or upon the authority of the Board of Directors of the Company (the “Board”).

2. Starting Date/Term. If you accept this offer, your employment with Response Genetics will begin on February 20, 2007 (“Commencement Date”). Thereafter, you will be expected to devote all of your working time to the performance of your duties at Response Genetics throughout your employment. Your employment will be for a term of three (3) years, with automatic one (1) year renewal terms thereafter (collectively, the “Term”) unless the Company or you give written notice to the other of at least ninety (90) days prior to the expiration of any Term of such party’s election not to further extend this Agreement. Any termination of your employment will be governed by the terms set forth in this Agreement.

You will be eligible to receive an annual target bonus, in the Company’s discretion and based upon the Company’s Bonus Plan applicable to officers and key employees, of up to 35% of your base salary, based upon the Company meeting certain targets and your meeting certain personal objectives as agreed upon by the CEO and approved by the Board. The target bonus will be calculated and awarded within 45 days of the end of the Company’s fiscal year.

(a) The Company shall grant to you on the date of the effectiveness of the Company’s initial public offering a nonqualified stock option, equal to 1.0% of the Company’s shares outstanding (calculated on an as-converted basis to Common Stock) on the Commencement Date (the “Option”), subject to the terms and conditions of the Company’s 2006 Stock Plan and Standard Form of Option Agreement. The exercise price of the Option shall be equal to the initial public offering price of the Company’s common stock. Should no IPO take place by September 25, 2007, the Company shall grant to you in lieu thereof on that date the Option and the exercise price shall be equal to the fair market value of the Company’s common stock on that date. The Option shall vest in equal annual amounts over a four (4) year period commencing on the first anniversary of the Commencement Date and each anniversary thereafter until fully vested, provided you remain employed during such period.

(i) Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing more than 50% of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions which the Board does not approve; or

(ii) Merger/Sale of Assets. (A) A merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (B) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; or

(iii) Change in Board Composition. A change in the composition of the Board, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” shall mean directors who either (A) are directors of the Company as of the Commencement Date, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company).

(iv) For purposes of this Agreement, “Change in Control” shall be interpreted in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences for either party with respect to Section 409A of the Internal Revenue Code of 1986, as amended (“Code Section 409A”), and any successor statute, regulation and guidance thereto.

(i) Should a Change of Control occur during the first year of your employment, you shall be entitled to a cash payment that is equivalent to six (6) months salary at your then current annual rate of pay to be paid bi-weekly, minus customary deductions for federal and state taxes and the like for six (6) months following the date of the Change of Control;

(ii) Should a Change of Control occur during the second or third years of your employment, you shall be entitled to a cash payment that is equivalent to nine (9) months salary at your then current annual rate of pay to be paid bi-weekly, minus customary deductions for federal and state taxes and the like, for nine (9) months following the date of the Change of Control;

(iii) If at the time a payment is to be made under this Section 3(c), it is determined that you are deemed to be a “specified employee” of the Company (within the meaning of Section 409A of the Code, as amended, and any successor statute, regulation and guidance thereto (“Code Section 409A”)), then limited only to the extent necessary to comply with the requirements of Code Section 409A, any payments to which you may become entitled under Section 3(c) which are subject to Code Section 409A (and not otherwise exempt from its application) will be withheld until the first (1^st) business day of the seventh (7th) month following the termination of your employment, at which time you shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to you under the terms of this Section 3(c);

(iv) If any payment or benefit you would receive under this Agreement, when combined with any other payment or benefit you receive pursuant to a Change of Control (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either (x) the full amount of such Payment or (y) such lesser amount (with cash payments being reduced before stock option compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal state and local employments taxes, income taxes, and the Excise Tax results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

(d) In addition to your compensation, you may take advantage of various benefits currently offered by the Company generally to its employees. Any such benefits may be modified or changed from time to time at the sole discretion of the Company. Where a particular benefit is subject to a formal plan (for example, medical insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable formal plan document.

You will be granted twenty (20) paid time off days (“PTO” days) for your use for vacation, personal or sick leave. Vacation should be scheduled upon consultation with the Chief Executive Officer and with advance notice. A total of five accrued but unused PTO days will be paid to you should you leave the Company’s employment. The Company will also observe 10 holidays per year, for which you will be paid.

4. Severance. In the event you are terminated without “Cause” as such term is defined below, or in the event that you resign “For Good Reason” as such term is defined below, you shall be entitled to severance, provided you first execute a release in a form reasonably satisfactory to the Company, upon the following terms:

(a) If during your first year of employment you are terminated without Cause, or if you resign For Good Reason, the Company shall pay you severance equivalent to six (6) months of your base salary, which severance shall be paid except as set forth in Section 4(e) below, in equal bi-weekly installments over a period of six (6) months provided you exercise a release in a form satisfactory to the Company. If during the second or third years of your employment, you are terminated without cause or if you resign for good reason, you shall be entitled to severance pay that is equivalent to nine (9) months salary at your then current annual rate of pay to be paid except as set forth in Section 4(e) below, bi-weekly, minus customary deductions for federal and state taxes and the like, for nine (9) months following the date of the Change of Control, provided you exercise a release in a form satisfactory to the Company.

(iv) For purposes of this Agreement, “Good Reason” shall be interpreted in a manner, and limited to the extent necessary, so that it will not cause adverse tax consequences for either party with respect to Section 409A of the Internal Revenue Code of 1986, as amended (“Code Section 409A”), and any successor statute, regulation and guidance thereto.

(e) Notwithstanding any other provision with respect to the timing of payments under this Section 4, if, at the time of your termination, you are deemed to be a “specified employee” of the Company within the meaning of Code Section 409A, then limited only to the extent necessary to comply with the requirements of Code Section 409A, any payments to which you may become entitled under Section 4 which are subject to Code Section 409A (and not otherwise exempt from its application) will be withheld until the first (1^st) business day of the seventh (7th) month following your termination of employment, at which time you shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to you under the terms of Section 4.

(f) The Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit set forth in this Agreement, including but not limited to consequences related to Code Section 409A. You and the Company agree to both negotiate in good faith and jointly execute an amendment to modify this Agreement to the extent necessary to comply with the requirements of Code Section 409A; provided that no such amendment shall increase the total financial obligation of the Company under this Agreement. In the event that the Company determines in good faith that it is required to withhold taxes from any payment or benefit already provided to you, you agree to pay on demand the amount the Company has determined to the Company.

5. Indemnity. The Company shall indemnify you and hold you harmless from any and all claims arising from or relating to your performance of your duties hereunder to the fullest extent permitted by law and/or the Company’s Directors and Officers Liability Insurance or other applicable document. .

(a) You hereby certify to Response Genetics that you are free to enter into and fully perform the duties of your position and that you are not subject to any employment, confidentiality, non-competition or other agreement that would restrict your employment by Response Genetics. You further hereby certify that your signing this letter of employment with Response Genetics does not violate any order, judgment or injunction applicable to you, or conflict with or breach any agreement to which you are a party or by which you are bound.

(b) You hereby certify that all facts you have presented or will present to Response Genetics are accurate and true. This includes, but is not limited to, all oral and written statements you have made (including those pertaining to your education, training, qualifications, licensing and prior work experience) on any job application, resume or c.v., or in any interview or discussion with Response Genetics.

(a) Definition: “Confidential Information” means all Response Genetics proprietary information, technical data, trade secrets, know-how and any idea in whatever form, tangible or intangible, including without limitation, research, product plans, customer and client lists, developments, inventions, processes, technology, designs, drawings, marketing and other plans, business strategies and financial data and information. “Confidential Information” shall also mean information received by Response Genetics from customers or clients or other third parties subject to a duty to keep confidential.

(b) Duty Not to Disclose: In connection with your employment by Response Genetics, you will be exposed to and have access to the Company’s Confidential Information. You agree to hold all Confidential Information in strict confidence and trust for the sole benefit of Response Genetics and not to, directly or indirectly, disclose, use, copy, publish, summarize, or remove any Confidential Information from the Company’s premises, except as specifically authorized in writing by the Company and in connection with the usual course of your employment. This duty supplements, but does not supersede, your professional and ethical obligations as the Company’s counsel.

(c) Documents and Materials: You further agree that you will return all Confidential Information, including all copies and versions of such Confidential Information (including but not limited to information maintained on paper, disk, CD-ROM, network server, or any other retention device whatsoever) and other property of the Company, to the Company immediately upon cessation of your employment with the Company. These terms are in addition to any statutory or common law obligations that you may have relating to the protection of the Company’s Confidential Information or its property. These restrictions shall survive the termination of your employment with Response Genetics.

8. Employment Terms. All Company employees are required, as a condition to your employment with the Company, to (i) sign and return a satisfactory I-9 Immigration form providing sufficient documentation establishing your employment eligibility in the United States; (ii) satisfactory proof of your identity as required by United States law; and (iii) abide by the Company’s Personnel Policies and Procedures as created by the Company and amended from time to time.

10. Miscellaneous. This letter constitutes the Company’s entire offer regarding the terms and conditions of your prospective employment with Response Genetics. It supersedes any prior agreements, or other promises or statements (whether oral or written) regarding the terms of employment. The terms of your employment shall be governed by the law of the State of California.

You may accept this offer of employment by signing the enclosed additional copy of this letter. Your signature on the copy of this letter and your submission of the signed copy to me will evidence your agreement with the terms and conditions set forth herein. This offer will expire on February 28, 2007 unless accepted by you prior to such date by directing the signed offer letter to the attention of Kathleen Danenberg.

		Sincerely,
		/s/ Kathleen Danenberg
		Kathleen Danenberg